CRO dMed raises $50m to advance global operations

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Martin Barraud)
(Image: Getty/Martin Barraud)

Related tags: dMed, CRO

dMed Biopharmaceutical recently raised approximately $50m in a Series B financing to further expand the CRO’s operations after launching three years ago.

The round was led by Vivo Capital, a health care-focused investment firm with offices in Palo Alto, Beijing, Shanghai, Hongkong, and Taipei.

Legend Capital, Qiming Venture Partners, and Lilly Asia Ventures also joined the round, funds from which will help expand dMed’s clinical operations and information technology infrastructure.

A full-service contract research organization (CRO), dMed has offices in Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and, since launching three years ago, today employs more than 600 professionals.

Dr. Lingshi Tan, founder and CEO of dMed, said in a statement: "We have delivered high-quality clinical trial services for over 200 projects, working with 80 innovative Chinese and global pharma companies since the company was set up, demonstrating the next-generation CRO at global capacity and standards.”

“After this round of financing, dMed will be able to serve more Chinese and global innovative pharma companies to help them effectively raise efficiency in clinical R&D, scientifically shorten research cycles, and boost success rates."

dMed also earlier this year completed the acquisition of Target Health, a full service NY-based CRO and opened a regulatory affairs office in the US.

 

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars